Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?

Related Experiment Video

Updated: Aug 16, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K

Konrad Zuzda1, Wiktoria Grycuk1, Jacek Małyszko2

  • 1Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Bialystok, Poland.

Expert Opinion on Therapeutic Targets
|December 22, 2022
PubMed
Abstract

Insights

Dyslipidemia contributes to chronic kidney disease (CKD) progression and cardiovascular risks. Novel therapies targeting lipid metabolism and mitochondrial dysfunction show promise for managing CKD and reducing associated mortality.

Area of Science:

  • Nephrology
  • Cardiology
  • Metabolic Diseases

Background:

  • Altered lipid metabolism and distribution are implicated in chronic kidney disease (CKD) development and progression.
  • Dyslipidemia is a significant risk factor for CKD, increasing cardiovascular event risk and mortality.

Purpose of the Study:

  • To review the role of lipids in kidney disease progression, lipotoxicity, and mitochondrial dysfunction.
  • To discuss current and emerging therapeutic strategies for dyslipidemia in CKD patients.

Main Methods:

  • Literature review focusing on lipid metabolism in kidney disease.
  • Analysis of current guidelines and clinical trial data for lipid-lowering therapies in CKD.
  • Examination of novel therapeutic agents and their mechanisms of action.

Main Results:

  • Statin therapy is the most common lipid-lowering treatment for CKD, though guidelines remain controversial.
  • Efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in CKD patients is not yet established.
  • Emerging therapies including PCSK9-small interfering RNA (siRNA), evinacumab, cyclodextrins, and FXR/TGR5 agonists show potential.

Conclusions:

  • Understanding lipid metabolism regulation in kidney disease is crucial.
  • Targeting mitochondrial dysfunction offers a potential therapeutic avenue for renal lipid disorders.
  • Further research is needed to evaluate novel agents for cardiovascular risk reduction and kidney function improvement in CKD.
Keywords:
Chronic kidney diseasedyslipidemialipidstherapeutic targets

More Related Videos

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.6K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
747
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
67
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
59
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
54
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.9K
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
18